The response to high-dose intravenous immunoglobulin or steroids is not predictive of outcome after splenectomy in adults with autoimmune thrombocytopenic purpura

Autor: Bertrand Godeau, Annette Schaeffer, Philippe Bierling, JM Vantelon, O. Tournilhac, Marc Ruivard, M. T. Caulier

Publikováno v: British journal of haematology. 105(4)

The response to high-dose intravenous immunoglobulin (IVIg) was recently reported to be predictive of outcome after splenectomy in patients with autoimmune thrombocytopenic purpura (AITP). We analysed the records of 75 adults with chronic AITP who re

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f458ea3f2b6115af12abaeebc97e9b3
https://pubmed.ncbi.nlm.nih.gov/10554833

Recherche de marqueurs d'auto-immunité au cours du purpura thrombopénique auto-immun idiopathique de l'adulte : résultats d'une étude monocentrique incluant 122 malades

Autor: A Schaeffer, C André, Philippe Bierling, JM Vantelon, Bertrand Godeau

Publikováno v: La Revue de Médecine Interne. 19:410

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ed01a286b5e34e27d69e4b480dd7fbb5
https://doi.org/10.1016/s0248-8663(98)90086-8

[Interest of crizotinib in a lung cancer patient with de novo amplification of MET].

Autor: Rabeau A; Service de pneumologie, hôpital Larrey, université Paul-Sabatier, CHU de Toulouse, 31400 Toulouse, France., Rouquette I; Service de pathologie, IUCT-Oncopole, CHU de Toulouse, 31100 Toulouse, France., Vantelon JM; Clinique de l'Occitanie, 31600 Muret, France., Taranchon-Clermont E; Service de pathologie, IUCT-Oncopole, CHU de Toulouse, 31100 Toulouse, France., Mazières J; Service de pneumologie, hôpital Larrey, université Paul-Sabatier, CHU de Toulouse, 31400 Toulouse, France. Electronic address: mazieres.j@chu-toulouse.fr.

Publikováno v: Revue des maladies respiratoires [Rev Mal Respir] 2017 Jan; Vol. 34 (1), pp. 57-60. Date of Electronic Publication: 2016 Oct 13.

Prognostic value of the age-adjusted International Prognostic Index in chemosensitive recurrent or refractory non-Hodgkin's lymphomas treated with high-dose BEAM therapy and autologous stem cell transplantation.

Autor: Jabbour E; Département de Médecine, Institut Gustave Roussy, Villejuif, France., Peslin N, Arnaud P, Ferme C, Carde P, Vantelon JM, Bocaccio C, Bourhis JH, Koscielny S, Ribrag V

Publikováno v: Leukemia & lymphoma [Leuk Lymphoma] 2005 Jun; Vol. 46 (6), pp. 861-7.

Multicenter phase II feasibility trial of high-dose tamoxifen in patients with refractory or relapsed multiple myeloma.

Autor: Decaudin D, Etienne MC, De Cremoux P, Maciorowski Z, Vantelon JM, Voog E, Urien S, Tran-Perennou C, Renée N, Vielh P, Némati F, Pouillart P

Publikováno v: Journal of the National Cancer Institute [J Natl Cancer Inst] 2004 Apr 21; Vol. 96 (8), pp. 636-7.